Scarica l'app Stockscreener
62.01
8.62%
-5.85
Pre-mercato:
61.23
-0.78
-1.26%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Incyte Corp Borsa (INCY) Ultime notizie
Analyst recommendations: Block, Incyte, Ralph Lauren, Five Below, Tesla... - Marketscreener.com
Incyte Corporation (INCY): Among the Best Biotech Stocks to Buy According to Billionaires - Yahoo Finance
Incyte stock dives after drug trial disappoints investors - Yahoo Finance
Incyte Corp. stock underperforms Monday when compared to competitors - MarketWatch
RBC maintains Incyte stock with $68 target post-data release By Investing.com - Investing.com Australia
Incyte stock tumbles despite meeting main goal in skin disease treatment trial - MSN
Incyte (INCY) Stock Drops on Phase Three Trial Data - GuruFocus.com
Why Incyte (INCY) Stock Is Nosediving - MSN
Leerink says Incyte’s povo trial results disappoint, drug likely to be approved - TipRanks
Oil pressures, Robinhood, Incyte: Market Minute - Yahoo Finance
Top Midday Decliners -March 17, 2025 at 02:00 pm EDT - Marketscreener.com
Incyte Reports Positive Results From Skin Therapy Study; Wells Fargo Cuts Price Target; Shares Drop - Marketscreener.com
Mizuho Reiterates Neutral Rating on Incyte (INCY) - StreetInsider.com
US MARKET Live, 17 March 2025: Incyte Corp, Tesla, and Dollar General among top losers on S&P 500 - Moneycontrol
Incyte stock hit 11% despite paediatric dermatology trials hitting target - Clinical Trials Arena
Incyte Leads S&P 500 Decliners Amidst Phase III Results of PovorcitinibNews and Statistics - IndexBox, Inc.
Incyte Leads S&P 500 Decliners on Skin Condition Drug Trial Results - Investopedia
Top Stock Movers Now: Intel, Netflix, Incyte, and More - Investopedia
Incyte Is Today’s Worst S&P 500 Stock. Here’s Why. - MSN
Nvidia, Netflix, Berkshire Hathaway, Baidu, Incyte, NCL, Affirm: Stocks to watch today - Yahoo Finance
Incyte stock decline after results an ‘overreaction,” says Wolfe Research - TipRanks
Incyte Stock Eyes Worst Day Since 2018 After Trial Results - Schaeffers Research
Wells Fargo Cuts Price Target on Incyte to $58 From $70 -March 17, 2025 at 10:34 am EDT - Marketscreener.com
Incyte could see some weakness as povo looks mostly as expected, RBC says - TipRanks
Incyte's New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls - Benzinga
Nvidia, Netflix, Berkshire Hathaway, Baidu, Lockheed Martin, Incyte, NCL, Affirm: Stocks to watch today - MSN
RBC maintains Incyte stock with $68 target post-data release - Investing.com
Incyte, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Buy Rating for Incyte’s Povorcitinib Despite Mixed Trial Results, Highlighting Potential in Biologic-Experienced Subgroups - TipRanks
Stocks making the biggest moves premarket: Affirm, Netflix, Incyte, Norwegian Cruise Line and more - CNBC
Incyte Reports Positive Data From Phase 3 STOP-HS Studies Of Povorcitinib - Nasdaq
Incyte stock tumbles following clinical trial results By Investing.com - Investing.com Australia
Incyte stock tumbles following clinical trial results - Investing.com
RBC Capital on Incyte (INCY): 'Povo Looks Mostly as We Expected', 'We expect modest weakness today' - StreetInsider.com
Incyte’s skin disease drug meets main goal in late-stage studies - The Financial Express
Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa - BioSpace
Incyte reports pivotal trial success for HS treatment povorcitinib - Investing.com
S&P 500 Futures Fall in Premarket Trading; Incyte, Affirm Holdings Lag - Barron's
Incyte's skin disease drug meets main goal in two late-stage studies -March 17, 2025 at 07:23 am EDT - Marketscreener.com
Incyte's skin disease drug meets main goal in two late-stage studies - TradingView
Incyte's skin disease drug meets main goal in two late-stage studies -March 17, 2025 at 07:06 am EDT - Marketscreener.com
15 Best Biotech Stocks to Buy According to Billionaires - Insider Monkey
INCY Opzelura Shows Superior Efficacy in 2 Prurigo Nodularis Studies - MSN
Atopic Dermatitis Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Patient Pool, MOA, ROA and Companies by DelveInsight - Barchart
Incyte’s SWOT analysis: stock faces patent cliff as dermatology pipeline grows By Investing.com - Investing.com South Africa
Incyte’s SWOT analysis: stock faces patent cliff as dermatology pipeline grows - Investing.com
Incyte (INCY) Up 2.6% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Incyte at Leerink Global Healthcare: Strategic Growth and Pipeline Focus - Investing.com
Incyte Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) - Benzinga
Incyte stock holds as JMP maintains Market Perform rating By Investing.com - Investing.com South Africa
Incyte stock holds as JMP maintains Market Perform rating - Investing.com
Incyte Releases Mixed Data From Late-Stage Opzelura Studies In Skin Disease Characterized By Itchy Firm Lumps - AOL
Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases - AOL
TD Cowen sets Incyte stock $88 target, retains Buy rating - Investing.com
LLY/INCY Olumiant Shows Superior Efficacy In Pediatric Alopecia Study - Barchart
Eli Lilly, Incyte Report Significant Hair Regrowth in Adolescents Treated With Baricitinib - Marketscreener.com
Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura®) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting - BioSpace
Incyte Corporation to Host Earnings Call - ACCESS Newswire
Incyte, Eli Lilly present results from Phase 3 BRAVE-AA-PEDS study - TipRanks
Incyte announces results from Phase 3 TRuE-PN trial - TipRanks
Opzelura May Reduce Need for Other Treatments in Atopic Dermatitis | AAD 2025 - Managed Healthcare Executive
Incyte Co. (NASDAQ:INCY) Stock Position Lowered by Mutual of America Capital Management LLC - Defense World
For Opzelura, Positive Results from One Trial, Less So From Another | AAD 2025 - Managed Healthcare Executive
Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study - Quantisnow
Incyte Corp (INCY) Announces Promising Phase 3 Trial Results for Ruxolitinib Cream in Treating Prurigo Nodularis - GuruFocus.com
Incyte Corp Says Phase 3 True-Pn1 Study Meets All Primary And Key Secondary Endpoints - Marketscreener.com
1.59%
3.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):